1
|
Kandasamy M, Ishitani H, Kobayashi S. Continuous‐Flow Synthesis of β‐Ketoesters and Successive Reactions in One‐Flow using Heterogeneous Catalysis. Adv Synth Catal 2022. [DOI: 10.1002/adsc.202200602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
2
|
Tang ML, Wen ZH, Wang JH, Wang ML, Zhang H, Liu XH, Jin L, Chang J. Discovery of Pyridone-Substituted Triazolopyrimidine Dual A 2A/A 1 AR Antagonists for the Treatment of Ischemic Stroke. ACS Med Chem Lett 2022; 13:436-442. [PMID: 35295085 PMCID: PMC8919384 DOI: 10.1021/acsmedchemlett.1c00599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 02/16/2022] [Indexed: 11/28/2022] Open
Abstract
![]()
Ischemic stroke is
a complex systemic disease characterized by
high morbidity, disability, and mortality. The activation of the presynaptic
adenosine A2A and A1 receptors modifies a variety
of brain insults from excitotoxicity to stroke. Therefore, the discovery
of dual A2A/A1 adenosine receptor (AR)-targeting
therapeutic compounds could be a strategy for the treatment of ischemic
stroke. Inspired by two clinical phase III drugs, ASP-5854 (dual A2A/A1 AR antagonist) and preladenant (selective
A2A AR antagonist), and using the hybrid medicinal strategy,
we characterized novel pyridone-substituted triazolopyrimidine scaffolds
as dual A2A/A1 AR antagonists. Among them, compound 1a exerted excellent A2A/A1 AR binding
affinity (Ki = 5.58/24.2
nM), an antagonistic effect (IC50 = 5.72/25.9 nM), and
good metabolic stability in human liver microsomes, rat liver microsomes,
and dog liver microsomes. Importantly, compound 1a demonstrated
a dose–effect relationship in the oxygen-glucose deprivation/reperfusion
(OGD/R)-treated HT22 cell model. These findings support the development
of dual A2A/A1 AR antagonists as a potential
treatment for ischemic stroke.
Collapse
Affiliation(s)
- Mei-Lin Tang
- School of Pharmacy, Human Phenome Institute, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| | - Zi-Hao Wen
- School of Pharmacy, Human Phenome Institute, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| | - Jing-Huan Wang
- School of Pharmacy, Human Phenome Institute, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| | - Mei-Ling Wang
- School of Pharmacy, Human Phenome Institute, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| | - Heyanhao Zhang
- School of Pharmacy, Human Phenome Institute, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| | - Xin-Hua Liu
- School of Pharmacy, Human Phenome Institute, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| | - Lin Jin
- Department of Anesthesia, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China
| | - Jun Chang
- School of Pharmacy, Human Phenome Institute, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| |
Collapse
|
3
|
Filho EV, Pinheiro EM, Pinheiro S, Greco SJ. Aminopyrimidines: Recent synthetic procedures and anticancer activities. Tetrahedron 2021. [DOI: 10.1016/j.tet.2021.132256] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
4
|
Sharif EU, Miles DH, Rosen BR, Jeffrey JL, Debien LPP, Powers JP, Leleti MR. Development of a Scalable and Practical Synthesis of AB928, a Dual A 2a/A 2b Receptor Antagonist. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00124] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ehesan U. Sharif
- Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
| | - Dillon H. Miles
- Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
| | - Brandon R. Rosen
- Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
| | - Jenna L. Jeffrey
- Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
| | - Laurent P. P. Debien
- Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
| | - Jay P. Powers
- Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
| | - Manmohan R. Leleti
- Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States
| |
Collapse
|